A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Clinical trial NCT05265975 · TERMINATED

Trial details

NCT number: NCT05265975
Sponsor: Antengene Corporation
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma Indolent Non-Hodgkin Lymphoma

Start date: 2022-04-07
Primary completion: 2024-12-31
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.